Background: Despite being recognised that nutritional intervention is essential, nutritional
support is not widely accessible to all patients. Given the incidence of nutritional risk and …

Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for
patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases …

Introduction Neoadjuvant therapy may improve survival compared with upfront surgery in
patients with resectable and borderline resectable pancreatic cancer, but high-quality …

Background: Pancreatic cancer has the highest mortality rate among all main cancer types
and is the fourth leading cause of cancer death in Australia. Objective: This review focuses …

Pancreatic cancer (PC) is an aggressive disease, with a growing incidence, and a poor
prognosis. Neoadjuvant treatments in PC are highly recommended in borderline resectable …

Objective: To evaluate whether detection of recurrent pancreatic ductal adenocarcinoma
(PDAC) in an early, asymptomatic stage increases the number of patients receiving …

Background Patients with chronic pancreatitis (CP) have an increased risk of pancreatic
cancer. We present the international consensus guidelines for surveillance of pancreatic …

Background Patients with chronic pancreatitis or pancreatic cancer commonly develop
exocrine pancreatic insufficiency, and may not be adequately treated with pancreatic …

The distinct biology of pancreatic cancer with aggressive and early invasive tumor cells, a
tumor promoting microenvironment, late diagnosis, and high therapy resistance poses major …

Highlights•PEI is a common condition in PC patients and should be actively looked for in PC
patients and treated with PERT.•In resected and borderline resectable patients PERT should …